Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin, Apatinib, and Camrelizumab in Dedifferentiated Liposarcoma
NCT06694324Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, Rivoceranib and camrelizumab in dedifferentiated liposarcoma (DDL), sponsored by Fudan University. Primary endpoint: Overall Response Rate up to 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicinRivoceranibcamrelizumab
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06694324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694324.